Compare Eversource Energy (D/B/A) Common Stock (ES) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eversource Energy (D/B/A) Common Stock vs Novavax Inc — how do they compare? Eversource Energy (D/B/A) Common Stock trades at $66.63 (market cap $24.77B), while Novavax Inc trades at $12.49 (market cap $2.11B). The key difference: Eversource Energy (D/B/A) Common Stock is far larger — about 11.7× Novavax Inc's market cap, and Eversource Energy (D/B/A) Common Stock pays a 4.79% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eversource Energy (D/B/A) Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| ES | NVAX | |
|---|---|---|
Market Cap | $24.77B | $2.11B |
Volume | 3,738,127 | 8,376,831 |
Sector | Utilities | Health |
52-Week High | $76.21 | $12.82 |
52-Week Low | $63.28 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $54.84B | $1.69B |
Dividend Yield | 4.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eversource Energy (ES) trades at $65.75, down 0.53% with neutral technical signals. The company maintains solid fundamentals with a 17.08 P/E ratio, 84.95% gross margin, and recent earnings beats in Q4 2025 and Q1 2026. Analyst consensus targets $73.75 with 31% buy ratings, while the company progresses on grid modernization projects and regulatory clarity in Connecticut.
ES offers steady utility exposure with 4.5% dividend yield and $26.5B capex plan supporting growth, though Q2 2026 earnings miss and regulatory uncertainty pose near-term risks. The stock presents value for income investors seeking regulated utility stability with infrastructure upside potential.
Novavax (NVAX) trades at $12.64, down slightly by 0.16% on the day. The stock shows a bullish technical signal with strong moving average and oscillator support. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of -$0.32 surpassing the -$0.38 estimate. The company is transitioning its business model toward a partnership-driven approach centered on its Matrix-M adjuvant technology, with recent regulatory approvals for its updated COVID-19 vaccine in major markets.
The outlook is mixed with strong analyst buy ratings (73.9%) and recent business developments providing catalysts, but significant financial risks remain including negative cash flows, high debt levels, and inconsistent profitability. Investment opportunity exists in the partnership strategy execution, while risks include execution challenges and competitive pressures in the vaccine market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Eversource Energy (D/B/A) Common Stock
Eversource Energy is a regulated utility holding company delivering electricity, natural gas, and water to customers in Connecticut, Massachusetts, and New Hampshire. It operates through electric distribution and transmission, natural gas distribution, and water distribution segments, via subsidiaries including CL&P, NSTAR, PSNH, Yankee Gas, and Aquarion.
Read more on ES →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
